title: Application of PET/CT in the development of novel anticancer drugs.
abstract: Combined positron emission tomography/computed tomography (PET/CT) is a relatively new imaging modality, combining the functional images of PET with the anatomical information of CT. Since its commercial introduction about 5 years ago, PET/CT has become an important tool in oncology. Currently, the technique is used for primary staging and restaging of cancer patients, as well as for surgery and radiation therapy planning. The abilities of PET/CT to measure early treatment response as well as drug distribution within the body make this technique very useful in the development of novel anticancer drugs. In this paper, the recent literature on the current role of PET/CT in drug development is reviewed.
authors.affiliation: Division of Clinical Pharmacology, Department of Medical Oncology,The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
authors.forename: David S
authors.initials: DS
authors.lastname: Boss
authors.forename: Renato Valdes
authors.initials: RV
authors.lastname: Olmos
authors.forename: Michiel
authors.initials: M
authors.lastname: Sinaasappel
authors.forename: Jos H
authors.initials: JH
authors.lastname: Beijnen
authors.forename: Jan H M
authors.initials: JH
authors.lastname: Schellens
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D009367:Neoplasm Staging / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D010879:Piperazines / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography; D011743:Pyrimidines / Q000493:pharmacokinetics; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate